A Study of Two Anti-HIV Drug Combinations in HIV-Infected Patients

Launched by PHARMACIA AND UPJOHN · Aug 30, 2001

Keywords

ClinConnect Summary

In this multicenter, open-label study, 45 HIV-1-positive patients receive either combination drug therapy with delavirdine (DLV), zidovudine (ZDV), and indinavir (IDV) or combination drug therapy with ZDV, lamivudine (3TC), and IDV. NOTE: Patients are treated for 24 weeks and may opt to continue on study for 24 additional weeks, if HIV-1 RNA is less than 5,000 copies/ml or at the investigator's discretion.

Gender

ALL

Eligibility criteria

• • Inclusion Criteria
• Patients must have:
• • HIV-1 positive.
• • CD4 count above 50.
• • HIV-1 RNA greater than 20,000.
• Prior Medication:
• Allowed:
• • Less than 1 month prior treatment with zidovudine.
• • Exclusion Criteria
• Prior Medication:
• Excluded:
• • Prior 3TC, protease inhibitors, or non-nucleoside reverse transcriptase inhibitors.
• • Prior ZDV of greater than 1 month total duration.
• Prior Treatment:
• Excluded:
• • Lamivudine.
• • Protease inhibitors.
• • Non-nucleoside reverse transcriptase inhibitors.